Success Metrics

Clinical Success Rate
94.1%

Based on 16 completed trials

Completion Rate
94%(16/17)
Active Trials
0(0%)
Results Posted
94%(15 trials)
Terminated
1(5%)

Phase Distribution

Ph phase_3
10
50%
Ph phase_4
2
10%
Ph not_applicable
1
5%
Ph phase_2
2
10%

Phase Distribution

0

Early Stage

2

Mid Stage

12

Late Stage

Phase Distribution15 total trials
Phase 2Efficacy & side effects
2(13.3%)
Phase 3Large-scale testing
10(66.7%)
Phase 4Post-market surveillance
2(13.3%)
N/ANon-phased studies
1(6.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

88.9%

16 of 18 finished

Non-Completion Rate

11.1%

2 ended early

Currently Active

0

trials recruiting

Total Trials

20

all time

Status Distribution
Completed(16)
Terminated(2)
Other(2)

Detailed Status

Completed16
unknown2
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
20
Active
0
Success Rate
94.1%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (13.3%)
Phase 310 (66.7%)
Phase 42 (13.3%)
N/A1 (6.7%)

Trials by Status

terminated15%
withdrawn15%
completed1680%
unknown210%

Recent Activity

0 active trials
Showing 5 of 20
completedphase_2

A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects

NCT02486406
completedphase_3

A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults

NCT02582632
completedphase_3

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis

NCT02219503
completed

Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C

NCT02803138
completed

eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs

NCT04047680
View all 20 trials

Clinical Trials (20)

Showing 20 of 20 trials
NCT02486406Phase 2

A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects

Completed
NCT02582632Phase 3

A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults

Completed
NCT02219503Phase 3

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis

Completed
NCT02803138

Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C

Completed
NCT04047680

eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs

Completed
NCT02581163

Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium

Completed
NCT02582671

The Effectiveness of ABT-450/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland

Completed
NCT02581189

Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada

Completed
NCT03549832Not Applicable

Comparative Study of Two Regiemns in Management of Sofosbuvir/Daclatasvir Failure

Completed
NCT02504099Phase 3

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma

Terminated
NCT02487199Phase 3

Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney Disease

Completed
NCT02207088Phase 3

Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease

Completed
NCT01782495Phase 2

A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients

Completed
NCT02476617Phase 3

Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults

Completed
NCT03296930Phase 4

Effect Of DAAs For Treatment Of HCV On Normal Kidney

Unknown
NCT02265237Phase 3

A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)

Completed
NCT02219477Phase 3

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis

Completed
NCT02806362Phase 3

Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease (ESRD) on Hemodialysis (HD)

Withdrawn
NCT02950870Phase 4

Efficacy Study to Evaluate the Effect of New Antiviral Drugs on HCV Infection.

Unknown
NCT02216422Phase 3

A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adults With Genotype 1b (GT1b) Infection

Completed

All 20 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
20